Idera Presents Preclinical Data on Novel Class of Toll-Like Receptor Antagonists
10 Novembre 2006 - 4:35PM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) today presented data for a novel
class of compounds which act as antagonists of specific Toll-Like
Receptors (TLR). In preclinical studies, these antagonists have
been shown to block immune activation through TLR7, 8, and 9, as
evaluated by use of agonists specific to these receptors. The
antagonists have been shown to be specific for TLR7, 8, and 9, as
immune activation by agonists to other TLRs was not blocked. The
oral presentation entitled �DNA-based antagonists for TLR7, 8, and
9: Potential applications in autoimmune disorders� (Abstract #
BRC2) was made at the Innate Immune Receptors and Responses session
during the American College of Rheumatology Basic Research
Conference being held in Washington, D.C., today beginning at 10:35
a.m. ET. �Our chemistry-based drug discovery platform allows us to
continually expand our understanding of the structure-activity
relationships of TLR modulators,� said Sudhir Agrawal, D. Phil.,
Chief Executive Officer and Chief Scientific Officer. �Through our
program we have identified a novel class of compounds that act as
antagonists for specific TLRs. We currently are evaluating these
antagonists in preclinical autoimmune disease models.� �Based on
the productivity of our drug discovery platform, we are developing
a broad portfolio of potential TLR modulators, including DNA-based
agonists of TLR9, RNA-based agonists of TLR7 and TLR8, and
DNA-based antagonists of TLR 7, 8 and 9,� commented Robert W. Karr,
M.D., President. �By inhibiting activation of immune responses
through TLR 7, 8, and 9, our novel antagonists may have potential
applications in the treatment of certain autoimmune diseases.�
About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug
discovery and development company that is developing drug
candidates to treat cancer and infectious, respiratory, autoimmune
diseases, and for use as vaccine adjuvants. Idera�s proprietary
drug candidates are designed to modulate TLRs, the body�s first
line of immune defense. Idera�s pioneering DNA chemistry expertise
enables it to identify drug candidates for internal development and
creates opportunities for multiple collaborative alliances. Idera�s
most advanced clinical candidate, IMO-2055, is an agonist of TLR9
and is currently in a Phase 2 monotherapy trial and a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonists for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera�s
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera�s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company�s
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies such as
the studies referred to in this release will be indicative of
results that may be obtained in clinical trials; whether Idera�s
cash resources will be sufficient to fund product development and
clinical trials; and such other important factors as are set forth
under the caption "Risk Factors" in Idera�s Quarterly Report on
Form 10-Q filed on August 14, 2006, which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements. Idera
Pharmaceuticals (AMEX: IDP) today presented data for a novel class
of compounds which act as antagonists of specific Toll-Like
Receptors (TLR). In preclinical studies, these antagonists have
been shown to block immune activation through TLR7, 8, and 9, as
evaluated by use of agonists specific to these receptors. The
antagonists have been shown to be specific for TLR7, 8, and 9, as
immune activation by agonists to other TLRs was not blocked. The
oral presentation entitled "DNA-based antagonists for TLR7, 8, and
9: Potential applications in autoimmune disorders" (Abstract #
BRC2) was made at the Innate Immune Receptors and Responses session
during the American College of Rheumatology Basic Research
Conference being held in Washington, D.C., today beginning at 10:35
a.m. ET. "Our chemistry-based drug discovery platform allows us to
continually expand our understanding of the structure-activity
relationships of TLR modulators," said Sudhir Agrawal, D. Phil.,
Chief Executive Officer and Chief Scientific Officer. "Through our
program we have identified a novel class of compounds that act as
antagonists for specific TLRs. We currently are evaluating these
antagonists in preclinical autoimmune disease models." "Based on
the productivity of our drug discovery platform, we are developing
a broad portfolio of potential TLR modulators, including DNA-based
agonists of TLR9, RNA-based agonists of TLR7 and TLR8, and
DNA-based antagonists of TLR 7, 8 and 9," commented Robert W. Karr,
M.D., President. "By inhibiting activation of immune responses
through TLR 7, 8, and 9, our novel antagonists may have potential
applications in the treatment of certain autoimmune diseases."
About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug
discovery and development company that is developing drug
candidates to treat cancer and infectious, respiratory, autoimmune
diseases, and for use as vaccine adjuvants. Idera's proprietary
drug candidates are designed to modulate TLRs, the body's first
line of immune defense. Idera's pioneering DNA chemistry expertise
enables it to identify drug candidates for internal development and
creates opportunities for multiple collaborative alliances. Idera's
most advanced clinical candidate, IMO-2055, is an agonist of TLR9
and is currently in a Phase 2 monotherapy trial and a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonists for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies such as
the studies referred to in this release will be indicative of
results that may be obtained in clinical trials; whether Idera's
cash resources will be sufficient to fund product development and
clinical trials; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on
Form 10-Q filed on August 14, 2006, which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024